Male Research Stack (Ultimate Recomposition Protocol)

Combination Kit: RAD-140, Ostarine, Cardarine Tablets & Retatrutide Lyophilized Vial

The Quadruple-Pathway Synergy | Maximal Anabolism & Systemic Metabolic Shifts

The 4Balance Codex: The Apex Recomposition Model. Simultaneous activation of selective androgen signaling (lean tissue accrual), PPARδ pathways (lipid oxidation engine), and Triple-Hormone receptor agonism (systemic energy homeostasis and appetite control).

Product Overview

The 4Balance Male Research Stack represents the absolute frontier of body composition research. This kit is designed for advanced protocols investigating "radical recomposition"—the simultaneous maximization of lean tissue accretion and minimization of adipose tissue.

This stack transcends traditional multi-agent models by combining three established oral research compounds with the vanguard of injectable metabolic therapies. It pairs the potent anabolic signaling of RAD-140 and the tissue-preserving properties of Ostarine with the endurance-enhancing effects of Cardarine. Furthermore, it integrates Retatrutide, the revolutionary "Triple G" agonist, to fundamentally alter systemic energy balance.

We provide the oral agents in precise, laboratory-grade 100-count Tablet formats for consistent daily administration, alongside the lyophilized Retatrutide peptide.

Mechanism of Action: The Synergistic Cascade

The research value of this stack lies in targeting four distinct physiological pillars to force a complete shift in body composition:

1. The Systemic Metabolic Reset (Retatrutide - 10mg Vial): Retatrutide is a GIP, GLP-1, and Glucagon receptor triple agonist. In research models, it exhibits profound synergy. The GLP-1/GIP action significantly dampens appetite signaling and improves insulin sensitivity. Crucially, the addition of Glucagon receptor agonism increases resting energy expenditure and promotes hepatic lipid catabolism, driving a caloric deficit and fat loss that exceeds dual-agonists.

2. The Potent Anabolic Drive (RAD-140 - 10mg Tablets): RAD-140 (Testolone) is a Selective Androgen Receptor Modulator (SARM) with a high affinity for skeletal muscle receptors. It provides the primary anabolic signal in this stack, driving muscle protein synthesis and strength gains even in energy-deficient states created by Retatrutide.

3. The Metabolic Engine (Cardarine - 10mg Tablets): Cardarine (GW-501516) acts as a PPARδ agonist. It is not hormonal. By activating this pathway, Cardarine shifts the organism's preferred fuel source from glucose to fatty acids. Research demonstrates this mechanism dramatically increases oxidative capacity and endurance, allowing subjects to maintain high output despite reduced caloric intake.

4. Lean Tissue Preservation (Ostarine - 25mg Tablets): Ostarine (MK-2866) is the foundational "anchor." In aggressive fat-loss protocols, muscle catabolism is a primary risk. Ostarine’s highly selective tissue action provides a crucial signal to preserve bone and muscle mass, ensuring weight lost is preferentially adipose tissue.

Primary Research Applications

In the 4Balance Research Array, this quadruple-mechanism stack is utilized for:

• Aggressive Body Recomposition: Modeling rapid, simultaneous changes in fat mass reduction and lean muscle hypertrophy.

• Muscle Sparing under Extreme Deficit: Investigating the protective effects of dual-SARM signaling during profound energy restriction mediated by triple-agonists.

• Metabolic Adaptation & Endurance: Studying how PPARδ activation compensates for metabolic slowdown during rapid weight loss.

Technical Specifications & Kit Contents

This research stack contains four separate components, providing extensive materials for long-duration protocols:

• Component 1 (Anabolic SARM): RAD-140 (Testolone) | 10mg Tablets (100 Count Bottle)

• Component 2 (Preservation SARM): Ostarine (MK-2866) | 25mg Tablets (100 Count Bottle)

• Component 3 (Metabolic Agonist): Cardarine (GW-501516) | 10mg Tablets (100 Count Bottle)

• Component 4 (Triple Agonist Peptide): Retatrutide | 10mg Lyophilized Vial

• Purity: All components ≥99% (HPLC Verified)

DISCLAIMER: FOR LABORATORY RESEARCH USE ONLY. This product is a combination of laboratory research chemicals intended strictly for in-vitro and in-vivo research and development. These products are not drugs, dietary supplements, or treatments for any medical condition. NOT for human consumption, veterinary use, or therapeutic application. Bodily introduction of any kind is strictly prohibited by law. Buyer assumes all responsibility for applicable regulations and appropriate use in a research setting.

Scientific References for Research Context: [1] The New England Journal of Medicine. (2023). Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, for People with Obesity: A Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Finding Phase 2 Trial. [2] Endocrinology. (2007). Pharmacological Characterization of a Novel Nonsteroidal Selective Androgen Receptor Modulator, RAD140: Evidence for Tissue-Selective Androgenic Activity. [3] Cell. (2008). AMPK and PPARdelta agonists are exercise mimetics. [4] Journal of Cachexia, Sarcopenia and Muscle. (2011). Selective androgen receptor modulators in preclinical and clinical development.